Ascendis Pharma A/S (ASND)

Ascendis Pharma Balance Sheet

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	539.09	559.54	392.16	444.77	446.27	584.52
Short-Term Investments	-	-	7.28	290.69	235.8	134.28
Cash & Short-Term Investments	539.09	559.54	399.44	735.46	682.06	718.8
Cash Growth	-13.82%	40.08%	-45.69%	7.83%	-5.11%	20.18%
Accounts Receivable	134.73	166.28	35.87	11.91	2.2	0.39
Other Receivables	12.52	11.16	19.9	13.72	20.99	6.96
Receivables	147.25	177.44	55.77	25.63	23.19	7.34
Inventory	302.02	295.61	208.93	130.67	75.41	-
Prepaid Expenses	29.42	28.27	38.58	31.72	25.23	13.99
Total Current Assets	1,018	1,061	702.72	923.47	805.89	740.13
Property, Plant & Equipment	101.76	98.71	110.63	129.1	126.05	108.11
Long-Term Investments	28.3	13.58	5.69	30.42	145.91	124.46
Goodwill	-	3.5	3.5	-	3.5	3.5
Other Intangible Assets	3.74	0.53	0.92	4.83	1.78	2.22
Other Long-Term Assets	3.16	2.32	2.13	1.92	1.81	1.38
Total Assets	1,155	1,179	825.59	1,090	1,085	979.79
Accounts Payable	78.6	96.39	94.57	101.03	59.42	21.9
Accrued Expenses	48.3	67.96	41.18	31.99	29.95	23.38
Current Portion of Long-Term Debt	466.45	476.05	407.1	399.19	-	-
Current Portion of Leases	15.83	15.48	14.17	13.79	7	6.86
Current Income Taxes Payable	1.61	1.22	2.3	5.49	0.2	0.3
Current Unearned Revenue	4.16	0.94	1.18	-	2.6	0.36
Other Current Liabilities	371.54	249.82	176.02	165.29	1.19	-
Total Current Liabilities	986.48	907.86	736.51	716.78	100.36	52.8
Long-Term Debt	247.55	287.53	138.38	-	-	-
Long-Term Leases	83.82	77.55	84.62	95.4	97.97	85.12
Long-Term Unearned Revenue	0.69	5	5.95	14.21	2.96	-
Long-Term Deferred Tax Liabilities	10.28	7.26	5.83	-	-	-
Other Long-Term Liabilities	-	-	-	-	-	3.16
Total Liabilities	1,329	1,285	971.28	826.39	201.29	141.08
Common Stock	8.28	8.15	7.75	7.68	7.65	7.22
Additional Paid-In Capital	2,516	2,444	2,123	2,113	2,108	1,729
Retained Earnings	-2,697	-2,560	-2,277	-1,860	-1,236	-1,030
Treasury Stock	-0.08	-0.11	-0.15	-0.15	-0.02	-
Comprehensive Income & Other	-1.27	1.78	0.72	3.45	3.78	133.03
Shareholders' Equity	-174.08	-105.71	-145.7	263.35	883.64	838.71
Total Liabilities & Equity	1,155	1,179	825.59	1,090	1,085	979.79
Total Debt	813.65	856.62	644.27	508.38	104.96	91.98
Net Cash (Debt)	-274.56	-297.07	-244.83	234.57	684.66	742.1
Net Cash Growth	-	-	-	-65.74%	-7.74%	32.17%
Net Cash Per Share	-4.56	-5.13	-4.35	4.18	12.50	14.66
Filing Date Shares Outstanding	61.1	59.84	56.61	56.04	56.78	53.75
Total Common Shares Outstanding	61.1	59.84	56.61	56.04	56.78	53.75
Working Capital	31.3	153	-33.79	206.69	705.53	687.33
Book Value Per Share	-2.85	-1.77	-2.57	4.70	15.56	15.60
Tangible Book Value	-177.82	-109.73	-150.12	258.52	878.36	832.99
Tangible Book Value Per Share	-2.91	-1.83	-2.65	4.61	15.47	15.50
Machinery	-	32.91	38.86	-	25.77	19.8
Leasehold Improvements	-	20.3	19.38	-	18.07	8.54

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q